{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:15:36Z","timestamp":1793196936986,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR220088"],"award-info":[{"award-number":["RR220088"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paula C. and Rodger O. Riney Blood Cancer Research Initiative Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41375-024-02391-8","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T03:03:11Z","timestamp":1724986991000},"page":"2355-2365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma"],"prefix":"10.1038","volume":"38","author":[{"given":"Jennifer","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-806X","authenticated-orcid":false,"given":"Stefan","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feda","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Shokeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Muz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-966X","authenticated-orcid":false,"given":"Katerina E.","family":"Miari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Maksimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Diedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obed","family":"Asare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinan","family":"Alhallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-0096","authenticated-orcid":false,"given":"Chaelee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Lubben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-9648","authenticated-orcid":false,"given":"Yixuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Adebayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Bash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5023","authenticated-orcid":false,"given":"Mark","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-4390","authenticated-orcid":false,"given":"Diane E.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1114-1418","authenticated-orcid":false,"given":"Mark T. S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2391_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"2391_CR2","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","volume":"113","author":"AK Azab","year":"2009","unstructured":"Azab AK, Runnels JM, Pitsillides C, Moreau A-S, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341\u201351.","journal-title":"Blood"},{"key":"2391_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, G\u00f6rg\u00fcn GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunological Rev. 2015;263:160\u201372.","journal-title":"Immunological Rev"},{"key":"2391_CR4","doi-asserted-by":"crossref","unstructured":"Uckun FM. Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma. Front Oncol. 2021;11.","DOI":"10.3389\/fonc.2021.760382"},{"key":"2391_CR5","doi-asserted-by":"crossref","unstructured":"Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. Bmj. 2020.","DOI":"10.1136\/bmj.m3176"},{"key":"2391_CR6","doi-asserted-by":"crossref","unstructured":"Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.00188"},{"key":"2391_CR7","doi-asserted-by":"crossref","unstructured":"Zhang C, Yang M, Ericsson AC. Function of macrophages in disease: current understanding on molecular mechanisms. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.620510"},{"key":"2391_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/cas.12167","volume":"104","author":"Y Komohara","year":"2013","unstructured":"Komohara Y, Niino D, Saito Y, Ohnishi K, Horlad H, Ohshima K, et al. Clinical significance of CD163+ tumor\u2010associated macrophages in patients with adult T\u2010cell leukemia\/lymphoma. Cancer Sci. 2013;104:945\u201351.","journal-title":"Cancer Sci"},{"key":"2391_CR9","doi-asserted-by":"crossref","unstructured":"Tong N, He Z, Ma Y, Wang Z, Huang Z, Cao H, et al. Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor\u2014glioma therapy? Front Cell Develop Biol. 2021;9.","DOI":"10.3389\/fcell.2021.706286"},{"key":"2391_CR10","doi-asserted-by":"crossref","unstructured":"Yang Y, Ye YC, Chen Y, Zhao JL, Gao CC, Han H, et al. Crosstalk between hepatic tumor cells and macrophages via Wnt\/\u03b2-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. Cell Death Dis. 2018;9.","DOI":"10.1038\/s41419-018-0818-0"},{"key":"2391_CR11","doi-asserted-by":"crossref","unstructured":"Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Science. 2019;26.","DOI":"10.1186\/s12929-019-0568-z"},{"key":"2391_CR12","doi-asserted-by":"crossref","unstructured":"Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M. The role of tumor-associated macrophages in hematologic malignancies. Cancers. 2021;13.","DOI":"10.3390\/cancers13143597"},{"key":"2391_CR13","doi-asserted-by":"crossref","unstructured":"Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, et al. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2021-003975"},{"key":"2391_CR14","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.7150\/jca.30102","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, Hu W-m, Xia Z-j, Liang Y, Lu Y, Lin S-x, et al. High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J Cancer. 2019;10:3239\u201345.","journal-title":"J Cancer"},{"key":"2391_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2016.06.018","volume":"85","author":"RL Lopes","year":"2016","unstructured":"Lopes RL, Borges TJ, Zanin RF, Bonorino C. IL-10 is required for polarization of macrophages to M2-like phenotype by mycobacterial DnaK (heat shock protein 70). Cytokine. 2016;85:123\u20139.","journal-title":"Cytokine"},{"key":"2391_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/bjc.2016.11","volume":"114","author":"H Wang","year":"2016","unstructured":"Wang H, Wang L, Chi P-d, Wang W-d, Chen X-q, Geng Q-r, et al. High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. Br J Cancer. 2016;114:463\u20138.","journal-title":"Br J Cancer"},{"key":"2391_CR17","doi-asserted-by":"crossref","unstructured":"Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Advances in Immunology2014. p. 177-210.","DOI":"10.1016\/B978-0-12-800267-4.00005-5"},{"key":"2391_CR18","doi-asserted-by":"crossref","unstructured":"Chen L, Shi Y, Zhu X, Guo W, Zhang M, Che Y, et al. IL\u201110 secreted by cancer\u2011associated macrophages regulates proliferation and invasion in gastric cancer cells via c\u2011Met\/STAT3 signaling. Oncology Reports. 2019.","DOI":"10.3892\/or.2019.7206"},{"key":"2391_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O\u2019Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170\u201381.","journal-title":"Nat Rev Immunol"},{"key":"2391_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33396-w","volume":"8","author":"K Maes","year":"2018","unstructured":"Maes K, Boeckx B, Vlummens P, De Veirman K, Menu E, Vanderkerken K, et al. The genetic landscape of 5T models for multiple myeloma. Sci Rep. 2018;8:15030.","journal-title":"Sci Rep."},{"key":"2391_CR21","doi-asserted-by":"crossref","unstructured":"Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, et al. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers. 2020;12.","DOI":"10.3390\/cancers12020305"},{"key":"2391_CR22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1080\/10428194.2021.1919657","volume":"62","author":"K Alhallak","year":"2021","unstructured":"Alhallak K, de la Puente P, Jeske A, Sun J, Muz B, Rettig MP, et al. 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leuk Lymphoma. 2021;62:2457\u201365.","journal-title":"Leuk Lymphoma"},{"key":"2391_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98760-9","volume":"11","author":"K Alhallak","year":"2021","unstructured":"Alhallak K, Jeske A, de la Puente P, Sun J, Fiala M, Azab F, et al. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Sci Rep. 2021;11:19343.","journal-title":"Sci Rep."},{"key":"2391_CR24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2217\/fon-2016-0057","volume":"12","author":"P de la Puente","year":"2016","unstructured":"de la Puente P, Azab AK. 3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma? Future Oncol. 2016;12:1545\u20137.","journal-title":"Future Oncol"},{"key":"2391_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","volume":"73","author":"P de la Puente","year":"2015","unstructured":"de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, et al. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015;73:70\u201384.","journal-title":"Biomaterials"},{"key":"2391_CR26","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","volume":"35","author":"K Alhallak","year":"2021","unstructured":"Alhallak K, Sun J, Wasden K, Guenthner N, O\u2019Neal J, Muz B, et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia. 2021;35:2346\u201357.","journal-title":"Leukemia"},{"key":"2391_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","volume":"270","author":"P de la Puente","year":"2018","unstructured":"de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, et al. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J Control Release. 2018;270:158\u201376.","journal-title":"J Control Release"},{"key":"2391_CR28","doi-asserted-by":"crossref","unstructured":"Alhallak K, Jeske A, de la Puente P, Sun J, Fiala M, Azab F, et al. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Scientific Reports. 2021;11.","DOI":"10.1038\/s41598-021-98760-9"},{"key":"2391_CR29","first-page":"100268","volume":"16","author":"J Sun","year":"2021","unstructured":"Sun J, Chen Y, Lubben B, Adebayo O, Muz B, Azab AK. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. Leuk Res Rep. 2021;16:100268.","journal-title":"Leuk Res Rep"},{"key":"2391_CR30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 2019;36:498\u2013511.e17.","journal-title":"Cancer Cell"},{"key":"2391_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","volume":"30","author":"YR Murciano-Goroff","year":"2020","unstructured":"Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30:507\u201319.","journal-title":"Cell Res"},{"key":"2391_CR32","doi-asserted-by":"crossref","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN Guidelines with the level of evidence. Cancers. 2020;12.","DOI":"10.3390\/cancers12030738"},{"key":"2391_CR33","doi-asserted-by":"crossref","unstructured":"Alhallak K, Sun J, Jeske A, Park C, Yavner J, Bash H, et al. Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges. Cancers. 2021;13.","DOI":"10.3390\/cancers13122853"},{"key":"2391_CR34","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8:e446\u2013e61.","journal-title":"Lancet Haematol"},{"key":"2391_CR35","doi-asserted-by":"crossref","unstructured":"Rothlin CV, Ghosh S. Lifting the innate immune barriers to antitumor immunity. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2020-000695"},{"key":"2391_CR36","doi-asserted-by":"crossref","unstructured":"Hirayama D, Iida T, Nakase H. The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis. Inter J Mol Sciences. 2017;19.","DOI":"10.3390\/ijms19010092"},{"key":"2391_CR37","doi-asserted-by":"crossref","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Targeted Ther. 2021;6.","DOI":"10.1038\/s41392-021-00506-6"},{"key":"2391_CR38","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114:3625\u20138.","journal-title":"Blood"},{"key":"2391_CR39","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/bit.25175","volume":"111","author":"RM Boehler","year":"2014","unstructured":"Boehler RM, Kuo R, Shin S, Goodman AG, Pilecki MA, Gower RM, et al. Lentivirus delivery of IL-10 to promote and sustain macrophage polarization towards an anti-inflammatory phenotype. Biotechnol Bioeng. 2014;111:1210\u201321.","journal-title":"Biotechnol Bioeng"},{"key":"2391_CR40","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.4049\/jimmunol.1000475","volume":"186","author":"A Dominguez-Soto","year":"2011","unstructured":"Dominguez-Soto A, Sierra-Filardi E, Puig-Kroger A, Perez-Maceda B, Gomez-Aguado F, Corcuera MT, et al. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol. 2011;186:2192\u2013200.","journal-title":"J Immunol"},{"key":"2391_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00395-017-0622-5","volume":"112","author":"M Jung","year":"2017","unstructured":"Jung M, Ma Y, Iyer RP, DeLeon-Pennell KY, Yabluchanskiy A, Garrett MR, et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol. 2017;112:33.","journal-title":"Basic Res Cardiol"},{"key":"2391_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/sji.12162","volume":"79","author":"S Mia","year":"2014","unstructured":"Mia S, Warnecke A, Zhang XM, Malmstrom V, Harris RA. An optimized protocol for human M2 macrophages using M-CSF and IL-4\/IL-10\/TGF-beta yields a dominant immunosuppressive phenotype. Scand J Immunol. 2014;79:305\u201314.","journal-title":"Scand J Immunol"},{"key":"2391_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1358\/dot.2013.49.09.2020941","volume":"49","author":"P de la Puente","year":"2013","unstructured":"de la Puente P, Azab AK. Contemporary drug therapies for multiple myeloma. Drugs Today (Barc). 2013;49:563\u201373.","journal-title":"Drugs Today (Barc)"},{"key":"2391_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19932-1","volume":"11","author":"C Federico","year":"2020","unstructured":"Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun. 2020;11:6037.","journal-title":"Nat Commun"},{"key":"2391_CR45","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.3324\/haematol.2016.142190","volume":"101","author":"P de la Puente","year":"2016","unstructured":"de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, et al. Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica. 2016;101:e307\u201311.","journal-title":"Haematologica"},{"key":"2391_CR46","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123:1542\u201355.","journal-title":"J Clin Invest"},{"key":"2391_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0227-3","volume":"9","author":"B Muz","year":"2019","unstructured":"Muz B, Azab F, Fiala M, King J, Kohnen D, Fogler WE, et al. Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy. Blood Cancer J. 2019;9:68.","journal-title":"Blood Cancer J"},{"key":"2391_CR48","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119:1468\u201378.","journal-title":"Blood"},{"key":"2391_CR49","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.3324\/haematol.2018.194688","volume":"104","author":"B Muz","year":"2019","unstructured":"Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, et al. PYK2\/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica. 2019;104:e310\u2013e3.","journal-title":"Haematologica"},{"key":"2391_CR50","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1080\/10428194.2017.1319052","volume":"58","author":"B Muz","year":"2017","unstructured":"Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, et al. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leuk Lymphoma. 2017;58:2916\u201325.","journal-title":"Leuk Lymphoma"},{"key":"2391_CR51","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.tranon.2017.04.010","volume":"10","author":"B Muz","year":"2017","unstructured":"Muz B, Azab F, de la Puente P, Landesman Y, Azab AK. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Transl Oncol. 2017;10:632\u201340.","journal-title":"Transl Oncol"},{"key":"2391_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.7","volume":"6","author":"P de la Puente","year":"2016","unstructured":"de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, et al. MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. Blood Cancer J. 2016;6:e399.","journal-title":"Blood Cancer J"},{"key":"2391_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.12734","volume":"165","author":"F Azab","year":"2014","unstructured":"Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, et al. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. Br J Haematol. 2014;165:89\u2013101.","journal-title":"Br J Haematol"},{"key":"2391_CR54","doi-asserted-by":"publisher","first-page":"112685","DOI":"10.18632\/oncotarget.22340","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X, Chen J, Zhang W, Sun R, Liu T, Zheng Y, et al. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget. 2017;8:112685\u201396.","journal-title":"Oncotarget"},{"key":"2391_CR55","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26:623\u201337.","journal-title":"Cancer Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02391-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02391-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02391-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:52:56Z","timestamp":1730281976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02391-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02391-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2073669\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Azab is the founder and owner of Cellatrix LLC that has an exclusive license for the 3DTEBM technology described in part of the experiments in this paper; however, Cellatrix has no contribution to this study. Other authors state no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}